Two hundred eighty-five patients, median age 42, with PML-RARa-positive acute promyelocytic leukaemia were randomised to Ara-C-containing 'Medical Research Council (MRC) Chemotherapy' þ ATRA (All-trans-retinoic acid) or anthracycline þ ATRA (modified 'Spanish') therapy. MRC treatment comprised four courses with ATRA in courses 1-2. Spanish treatment comprised four anthracycline-based courses with ATRA in courses 1-3. In course 3 patients were randomised to gemtuzumab ozogamicin (GO) or not. The Spanish arm received 24-month maintenance. Patients were sequentially molecularly monitored. Quality of life was assessed at baseline, 3, 6, 9, 12, 24 months. Remission rates were similar in both arms (93%): cumulative incidence of haematological relapse (CIHR) was 6% at 5 years; 5 patients relapsed molecularly. Survival post relapse was 80%. There were more deaths in remission in the MRC arm (4% vs 10%: P ¼ 0.2). The overall 5-year relapse-free and overall survival was similar between arms (81% vs 82% and 84% vs 83%, respectively). More supportive care and hospitalisation (81.8 vs 63 days, Po0.0001) was required in the MRC arm. GO did not provide benefit. High white blood cell count (410 Â 10 9 /l) was not prognostic overall, or within treatment arms. Both approaches deliver similar results with minor differences in quality of life. MRC treatment required more hospitalisation. This suggests that additional chemotherapy, Ara-C in particular, is not required.
INTRODUCTION
The introduction of All-trans-retinoic acid (ATRA), and subsequently arsenic trioxide (ATO) are landmark examples of targeted treatment of cancer. The preclinical observation of sensitivity in cell culture, which was applied in the clinic, was subsequently validated by molecular mechanistic studies. Although not able to effect cure as monotherapy, ATRA has dramatically enhanced chemotherapy such that 480% of patients entering clinical trials can now be cured. [1] [2] [3] [4] [5] Some questions, however, remain to be resolved, one of which is the intensity and duration of the associated chemotherapy, and more recently whether chemotherapy is required at all. Although anthracycline-based studies have been at the forefront of this improvement, it is not clear whether Ara-C and other chemotherapeutic agents or maintenance is required, and whether the trend to treatment de-escalation can be applied to higher-risk patients who present with a high white blood cell (WBC) count, with or without a low platelet count. When maintenance chemotherapy has been combined with ATRA, or ATRA given alone in two randomised trials there was a superior disease-free and overall survival. 4, 6 However, a recently updated Italian study in patients in molecular remission at the end of consolidation who were randomised to the maintenance options which were: chemotherapy alone (6-mercaptopurine and methotrexate)/ATRA þ chemotherapy/ ATRA alone/no maintenance, found no difference in disease-free or overall survival at 12 years. 7 This observation has been confirmed by a less-mature study from Japan. 8 When designing the acute promyelocytic leukaemia (APL) component of the UK MRC AML15 Trial, there was little evidence to suggest that maintenance was not required, so it was retained as a component of the modified 'Spanish' schedule. But the more pressing issue was whether the intensity of chemotherapy, which was Daunorubicin/cytarabine/etoposide-based, was more than was required. We therefore aimed to compare the combination of our standard chemotherapy combined with ATRA as used in our previous MRC AML12 trial, 5 with the Spanish anthracycline and ATRA approach with respect to conventional efficacy outcomes, molecular responses, resource use and quality of life measurements. hydroxycarbamide), pregnant or lactating women or those with concurrent active malignancy. Patients had a t(15;17) translocation confirmed locally and molecular analysis was undertaken in a central reference lab where they were characterised for the PML-RARa and the reciprocal RARa-PML transcripts.
Ethical considerations
The trial was approved by the Wales Multicentre Research Ethics Committee and each institution's ethical committee in accordance with the Declaration of Helsinki, and registered as ISRCTN17161961.
Randomisation and treatment
Participants were randomly allocated in a 1:1 ratio to the 'MRC Treatment' or the 'Spanish Treatment', the details of which are set out in Figure 1 . In consolidation, 172 patients from both arms were randomised to receive gemtuzumab ozogamicin (GO) (Mylotarg) 3 mg/m 2 on day 1 of course 3 of chemotherapy. Patients were longitudinally molecularly monitored for minimal residual disease at 3 monthly intervals for 3 years. If molecular positivity was detected at a level of 1 in 10 4 , or in the case of frank relapse, it was advised that the patients were treated with ATO followed by autologous or allogeneic transplantation. Our experience of monitoring and intervention has been reported in detail elsewhere. 9 Investigators were advised to be vigilant for signs of differentiation syndrome (unexplained fever, weight gain, respiratory distress, interstitial pulmonary infiltrates and pleural or pericardial effusion, with or without hyperleukocytosis), the treatment of which was cessation of ATRA, dexamethasone 10 mg IV 12 hourly and diuresis. From diagnosis, patients should have fibrinogen levels supported to the normal range and platelets to 50 Â 10 9 /l. The management of infection was undertaken in accordance with local policies, and growth factor support was not recommended, but was not prohibited.
End points
A primary end point of the study was comparison of the treatment impact on quality of life and resource use. The quality of life instrument was the EORTC QLQ-30C together with the Hospital Anxiety and Depression Scale. Patients were requested to complete this at baseline, and at 3, 6, 12 and 24 months following entry. End point definitions follow those of the International Working Group, 10 with two additions: first, complete response is presented here (to include both those with and without count recovery), and to take into account molecular monitoring, and the incidence of secondary acute myeloid leukaemia (AML) (a relapse other than APL), end points are created for molecular and frank relapse (with the cumulative incidence of molecular relapse denoted CIMR, frank relapse CIHR and secondary AML or MDS CITAML).
Statistical considerations
The primary outcome for this comparison was Quality of Life. A total of 292 patients would allow a difference of 1/3 of a s.d. in quality of life scores with 80% at a significance of P ¼ 0.05 to be detected at any given time point; the use of repeated measures analysis would increase this power, depending on the correlation between different time points. A similar number of patients would give similar power to detect a 13% difference in survival between groups. All analyses are by intention to treat, with the exception of six patients who were excluded because the initial diagnosis of APL proved to be incorrect, because of no evidence of a PML/RARa rearrangement. These patients were given appropriate AML therapy. All survival percentages are Kaplan-Meier estimates at 5 years. Dichotomous outcomes, such as complete response are compared using the MantelHaenszel test, and time-to-event outcomes using the log rank test. In both instances effect sizes (odds/hazard ratios (HR)) and 95% confidence intervals are given. Resource usage is compared using the Wilcoxon rank sum test. Quality of life data is analysed using repeated measures analysis to give an overall difference under a symptomatic relief (that is, a difference in values as opposed to a disease-modifying assumption of increasing difference over time) assumption with missing data treated as being missing at random. Response to induction treatment Ninety-three percent of patients on each arm achieved a complete morphological response (CR) ( Table 2 ). There was no difference in the rate or kinetics of the achievement of molecular negativity (median 72 days (MRC) vs 69 days (Spanish) P ¼ 0.8) overall, or when analysed by presenting WBC count o/X10 Â 10 9 /l, median days 70 days (WBCo10) vs 71 days (WBCX10). In the MRC and Spanish arms 7% and 6%, respectively, had induction deaths (death within 30 days), and a 60-day mortality rate of 8% vs 7%. Sixteen patients on the MRC arm and 16 on the Spanish died after this point, of whom 4 vs 8, respectively, had relapsed. Ten patients 
RESULTS

Between
Relapse
A total of 15 patients had a frank haematological relapse (9 Spanish, 6 MRC) confirmed by the presence of PML-RARa, giving a 5-year CIHR of 6% (7% vs 5% HR 1.39 (0.51-3.84) P ¼ 0.5, Figure 3a ). This was preceded by molecular relapse in 12 cases (8 Spanish, 4 MRC): an additional 5 patients (3 vs 2) experienced a molecularly detected relapse (defined as patients becoming positive by real time quantitative (RQ)-PCR for PML-RARa in two successive samples), which did not translate into haematological relapse, giving a CIMR of 8% at 5 years, which was not significantly different between the arms (9% vs 6% HR 1.41 (0.59-3.39) P ¼ 0.4, Figure 3b ). In patients with molecular relapse the advised intervention treatment was ATO given pre-emptively. Of the 15 patients who had a haematological relapse 12 (80%) were salvaged: if the 20 patients who had either molecular or haematological relapse were considered, the salvage rate was identical (16/20, 80% ). An additional 9 (7 Spanish, 2 MRC) patients relapsed with AML without the PML-RARa transcript, and were considered to have secondary disease. As observed previously, this rate of secondary disease was higher in the Spanish arm than the MRC arm although this difference was not significant (5-year CITAML (cumulative incidence of T-AML/MDS) 6% vs 2% HR 2.90 (0.79-10.7) P ¼ 0.11, Figure 3c ). Among patients experiencing haematological relapse, numbers with central nervous system involvement were not significantly different between arms (3 Spanish vs 1 MRC).
Deaths in remission Twenty-one patients died in remission with neither haematological or molecular relapse (8 Spanish, 13 MRC; 5-year CIDCR 4% vs 10% HR 0.59 (0.25-1.39) P ¼ 0.2, Figure 3d ). Over half of these deaths (11/21) occurred within 6 months of remission, with a significant excess of early deaths in the MRC arm (10 deaths within 6 months vs 1 Spanish; P ¼ 0.006 for CIDCR in first 6 months). The causes in the Spanish/MRC arms were infection 2/8: haemorrhage 0/1: other cancer 3/1: sudden 0/1: multiple 0/1: other/unknown 3/1.
Relapse-free and overall survival Any beneficial effect of a lower relapse/secondary AML rate in the MRC arm is offset by excess deaths in remission, so that the relapse-free survival was similar in both arms (81% vs 82% HR 1.11 (0.64-1.94), P ¼ 0.7, Figure 3e ). The overall survival at 5 years was 84% vs 83% (HR 0.92 (0.54-1.57), P ¼ 0.8, Figure 3f ).
Interactions with baseline covariates There were no significant interactions between induction treatment and any baseline covariates for overall survival (Supplementary Figure 1) . In particular, the effect of treatment was not modified by Sanz score (low: WBC o10, platelets X40; intermediate: WBC o10 platelets o40; high: WBC X10; P ¼ 0.9 for heterogeneity, P ¼ 0.7 for trend). Of interest, in this patient population, the Sanz risk group was not a significant prognostic factor either in overall analyses adjusted for treatment arm (P ¼ 0.6 for trend over three groups, P ¼ 0.08 high vs intermediate/low), nor in either treatment arm (MRC P ¼ 0.9; Spanish P ¼ 0.6 for trend), although numbers are too small to rule out a small effect.
Resource use and quality of life The Spanish arm resulted in delayed neutrophil and platelet recovery in courses 1-3, although there was significantly better platelet recovery in course 4. However, generally speaking, following the initial course, there was a requirement for greater supportive care and resource usage in the MRC arm; this was most evident after the 4th course. The average total number of days in hospital were, respectively, 81.8 in the MRC arm and 63.0 in the Spanish arm (Po0.0001 by Wilcoxon rank sum test). With the exception of oral toxicity in course 1, the Spanish arm showed no evidence of increased toxicity compared with the MRC arm; indeed the MRC arm was associated with worse alopecia in courses 1 and 2 and worse diarrhoea in course 2 ( Table 3 ). The quality of life data is illustrated in Figure 4 . Overall, on multilevel analysis there was evidence that quality of life was no worse on the Spanish arm (Figure 4a , effect size 5.30, 95% CI ( À 0.01-10.62, P ¼ 0.05), with evidence of significant benefit for Spanish therapy during the treatment period. Overall quality of life improved following treatment on both arms. There were no significant differences in any of the subscales, although there was a trend towards benefit for the Spanish arm in the social functioning scale (Figure 4f , effect size 6.75 ( À 0.73-14.22) P ¼ 0.08). In all subscales the greatest difference was seen at 3 months, with little or no difference between the treatments beyond 12 months, demonstrating that any differences in quality of life are likely to be transient, and that neither arm appears to show a disadvantage to patients in the long-term.
Consolidation treatment
There was no significant difference in survival between the GO and no GO consolidation arms (HR 2.22 (0.83-5.93), P ¼ 0.11, Figure 5a , Table 2), with outcomes for those entering the GO randomisation not significantly different than for those not entering. In particular, there were no differences in relapse of any kind (Figures 5b and c) , between treatment arms with the worse survival in the GO arm arising from an excess of deaths in CR in patients in this arm (5-year CIDCR 9% vs 0%, HR 4.90 (1.33-18.1), P ¼ 0.02, Figure 5d) Abbreviations: CI, confidence interval; CIDCR, cumulative incidence of death in complete remission; CIHR, cumulative incidence of haematological relapse; CIMR, cumulative incidence of molecular relapse; CITAML, cumulative incidence of secondary AML/MDS; GO, gemtuzumab ozogamicin; HR, hazard ratio; HRFS, haematological relapse free survival; MRFS, molecular relapse free survival; OS, overall survival. pattern in the causes of mortality in CR. There were no significant interactions between GO treatment and any baseline parameters or induction treatment, with the exception of a worse outcome with GO for female patients. We reported in our previous trial that molecular positivity after consolidation was, together with high presenting WBC count, highly correlated with relapse. 5 The presenting WBC in this trial did not correlate with rates of molecular response. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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DISCUSSION
The addition of ATRA to chemotherapy has dramatically improved the survival of patients with APL. Its proapoptotic effect sensitises the disease to chemotherapy such that if treatment is delivered without incident in the first couple of weeks there is a 490% chance of cure. The discovery of ATO in this context provides an effective therapy for patients who fail to achieve or sustain molecular response, and its adoption as consolidation has also been beneficial. 11 However, a number of questions remain to be resolved. Early diagnosis and therapy remains crucial and there has been recent concern that the results achieved from clinical trials do not represent the real outcome because of early, usually haemorrhagic, deaths before the chance of trial entry or therapy initiation. 12, 13 There is little doubt that a suspected case of APL represents a medical emergency, which requires immediate intervention with ATRA and coagulation support with platelets and coagulation factors.
14 Given the landmark studies of the Italian and Spanish APL groups' attenuation of the chemotherapy component to primarily anthracycline alone, the requirement for additional chemotherapeutic agents is in question, in particular the role of cytarabine. 15 Without additional chemotherapy 2-year survivals of 82% have been achieved. 1, 2 The European APL Group have retained cytarabine on the basis that its exclusion resulted in a higher risk of relapse, and have reported 1-year survivals of 91%. 3 The Italian and Spanish Groups still intensify the anthracycline component of chemotherapy in high-risk disease, which is defined as a presenting WBC count in excess of 10 Â 10 9 /l. The question arises as to whether the inclusion of cytarabine is detrimental with respect to deaths in remission, greater toxicity and requirement for supportive care and hospitalisation and quality of life, or whether it has advantages with respect to control of disease. In our previous MRC AML 12 trial the cumulative incidence of relapse for low and high WBC count patients was 10 and 33% respectively, but the risk of deaths in remission was 6%. The average number of neutropenic days and hospitalisation was 141 and 107 days. 5 The AML15 trial aimed to compare the effect of additional non-anthracycline chemotherapy with respect to efficacy, toxicity, resource requirements and quality of life. In all these respects additional chemotherapy did not provide any measurable benefit, and indeed required significantly more resource. In this trial, if the 142 patients allocated MRC treatment had been treated on the 'Spanish' arm, a total of 2670 hospital days would have been saved, or about 19 days per patient. This study supports the notion that Ara-C and other chemotherapy beyond anthracycline is not required. Of particular concern with respect to de-escalation of chemotherapy and the potential of adopting a 'chemo-free' approach [16] [17] [18] [19] is whether it is safe in the higher-risk subgroups. We found that high WBC count was not a significant prognostic factor in this trial, and did not moderate our findings with respect to the induction comparisons, although numbers are too small to rule out a small effect.
There are additional issues yet to be completely resolved. In AML15, maintenance therapy was routinely given for 24 months in the modified Spanish arm. But the benefit of maintenance has been questioned with the recent report of long-term follow-up of patients, who were in molecular remission after consolidation, to maintenance or not, which showed no difference in outcome. 7 In our study the rate of relapse after day 60 was superior in the 'Spanish' arm which included maintenance (Figure 3b) . A second area of controversy is the role of sequential molecular monitoring. This policy is viable with considerable laboratory expertise on marrow samples, but less reliably on peripheral blood. We have previously reported the UK experience of MRD monitoring in APL patients some of whom were included in the AML15 trial. 9 However, in AML15 the survival benefit of wholesale inclusion of MRD monitoring was not clear. Fifteen patients had a haematological relapse, which was preceded by a molecular relapse in 12 cases, of whom 1 received GO alone, 1 received ATO alone and 2 received arsenic þ GO at the time of molecular relapse. Among the eight patients who were not treated at the time of molecular relapse, all relapsed within 3 months, with four patients relapsing morphologically in the month following molecular relapse. For patients treated pre-emptively, three out of four relapsed X6 months after molecular positivity. Although the protocol included routine monitoring, three patients relapsed without a recorded molecular relapse and five had a molecular relapse but did not relapse after the recommended intervention. A further nine patients relapsed with secondary disease. They did not have the PML-RARa or RARa-PML transcripts at relapse and so were not amenable to detection. The policy of monitoring is predicated on the expectation that patients will have a better outcome if re-treated at the time of molecular rather than haematological relapse, which has been supported by unrandomised comparisons, 20, 21 which preceded the introduction of ATO as an effective treatment of relapse. In the limited experience in this trial the outcome of salvage after haematological and molecular relapse was the same, so the advantage of early detection and early intervention with ATO may be the avoidance of hyperleukocytosis, which can be problematic in the use of ATO in haematological relapse. Future exploration of a 'chemo-free' approach, however, should be supported by MRD detection to minimise risk in the experimental treatment. Although GO has clear efficacy in this disease, its addition in a small dose as additional consolidation provided no benefit, as the relapse risk by that time was already small.
Our conclusion from this trial is that it is acceptable to deescalate treatment by removing non-anthracycline treatment irrespective of risk group. The emerging data indicate that it may be possible to further de-escalate to a 'chemo-free' option, but this requires to be prospectively established. The benefits may not be in overall survival but reduced myelosuppression and its consequences.
